Advanced Or Metastatic Urothelial Carcinoma clinical trials

Explore recruiting advanced or metastatic urothelial carcinoma clinical trials.

Recruiting advanced or metastatic urothelial carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Or Metastatic Urothelial Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

​A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A​

Spain, Netherlands, Italy, Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Clofarabine Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: a Phase 1/2 Dose-Escalation Study

Austria

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).

Netherlands, Germany, Norway, Denmark, France, Austria +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

France, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Or Metastatic Urothelial Carcinoma trials by city

Advanced Or Metastatic Urothelial Carcinoma in Toronto Advanced Or Metastatic Urothelial Carcinoma in Vancouver Advanced Or Metastatic Urothelial Carcinoma in Montreal Advanced Or Metastatic Urothelial Carcinoma in Calgary Advanced Or Metastatic Urothelial Carcinoma in Edmonton Advanced Or Metastatic Urothelial Carcinoma in Ottawa Advanced Or Metastatic Urothelial Carcinoma in Winnipeg Advanced Or Metastatic Urothelial Carcinoma in Quebec City Advanced Or Metastatic Urothelial Carcinoma in Hamilton Advanced Or Metastatic Urothelial Carcinoma in Kitchener Advanced Or Metastatic Urothelial Carcinoma in London Advanced Or Metastatic Urothelial Carcinoma in Halifax Advanced Or Metastatic Urothelial Carcinoma in New York Advanced Or Metastatic Urothelial Carcinoma in Los Angeles Advanced Or Metastatic Urothelial Carcinoma in Chicago Advanced Or Metastatic Urothelial Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease